We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

Back to rankings

138 hedge funds and large institutions have $274M invested in Insys Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 49 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 21

0% more funds holding

Funds holding: 138 → 138 (0)

16% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 49

29% less capital invested

Capital invested by funds: $383M → $274M (-$109M)

52% less call options, than puts

Call options by funds: $3.44M | Put options by funds: $7.11M

Holders
138
Holders Change
–
Holders Change %
0%
% of All Funds
3.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
41
Reduced
49
Closed
21
Calls
$3.44M
Puts
$7.11M
Net Calls
-$3.66M
Net Calls Change
-$2.61M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$6.43M
2
RIA
Regal Investment Advisors
Michigan
+$2.59M
3
AC
Ascend Capital
California
+$2.54M
4
BFA
BlackRock Fund Advisors
California
+$1.84M
5
Credit Agricole
Credit Agricole
France
+$1.36M

Top Sellers

Rank Fund Capital Flow
1
SCM
Scopia Capital Management
New York
-$22.6M
2
State Street
State Street
Massachusetts
-$8.87M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.26M
4
FCM
Freshford Capital Management
New York
-$4.51M
5
Citadel Advisors
Citadel Advisors
Florida
-$3.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
SIM
126
Sonora Investment Management
Arizona
$5.52K – – –
EF
127
Empirical Finance
Pennsylvania
$5K +$4.97K +440 New
LTFS
128
Ladenburg Thalmann Financial Services
Florida
$4K -$7.63K -675 -58%
Acadian Asset Management
129
Acadian Asset Management
Massachusetts
$4K – – –
GXMC
130
Global X Management Company
New York
$3K – – –
WA
131
WealthTrust-Arizona
Arizona
$2K – – –
MWM
132
MinichMacGregor Wealth Management
New York
$2K +$2.82K +250 New
PIA
133
Piedmont Investment Advisors
North Carolina
$1.17K – – –
OAJ
134
Ogorek Anthony Joseph
New York
$1K – – –
PWM
135
Perigon Wealth Management
California
$1K – – –
PO
136
Private Ocean
California
$1K +$1.47K +130 New
FCM
137
Freshford Capital Management
New York
– -$4.51M -382,283 Closed
American Century Companies
138
American Century Companies
Missouri
– -$1.59M -135,063 Closed
RSCM
139
Rock Springs Capital Management
Maryland
– -$1.18M -100,000 Closed
SC
140
Sculptor Capital
New York
– -$875K -74,200 Closed
RCM
141
Raging Capital Management
New Jersey
– -$870K -73,760 Closed
D.E. Shaw & Co
142
D.E. Shaw & Co
New York
– -$591K -50,147 Closed
CIP
143
Convergence Investment Partners
Florida
– -$529K -44,905 Closed
AIMCA
144
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
– -$299K -25,400 Closed
HI
145
HBK Investments
Texas
– -$257K -21,837 Closed
PI
146
Putnam Investments
Massachusetts
– -$240K -20,354 Closed
UBS AM
147
UBS AM
Illinois
– -$210K -17,800 Closed
SIM
148
Strategic Investment Management
Virginia
– -$193K -16,400 Closed
AP
149
AHL Partners
United Kingdom
– -$183K -15,543 Closed
GS
150
GAM Systematic
United Kingdom
– -$179K -15,180 Closed
3 4 5
6
7

INSY Hedge Fund Activity: Q4 2016 in Review

138 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q4 2016, worth a combined $274M — down 29% from $383M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new INSY positions and 21 closed out — a net gain of 2 holders — while 41 added to existing stakes and 49 trimmed.

The largest buyer was OrbiMed, adding an estimated $6.43M. The largest seller was Scopia Capital Management, cutting an estimated $22.6M.

  • 138 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $274M of Insys Therapeutics, Inc. stock for Q4 2016, down 29% quarter-over-quarter.
  • 23 funds opened new Insys Therapeutics, Inc. positions in Q4 2016 and 21 closed out, a net change of +2 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q4 2016 was OrbiMed, an estimated $6.43M added.
  • The largest Insys Therapeutics, Inc. seller in Q4 2016 was Scopia Capital Management, an estimated $22.6M sold.

Based on aggregated 13F filings for Q4 2016.